$1.96
At close: Apr 15 EDT
$2.02
0.063.06%
Pre-Market: 6:17 AM EDT
Comments
Loading...
Artiva Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:ARTV | Benzinga
Artiva Biotherapeutics Inc has a consensus price target of $20 based on the ratings of 7 analysts. The high is $23 issued by Needham on April 8, 2025. The low is $18 issued by Wedbush on March 25, 2025. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Wedbush on April 8, 2025, March 26, 2025, and March 25, 2025, respectively. With an average price target of $20.33 between Needham, HC Wainwright & Co., and Wedbush, there's an implied 906.60% upside for Artiva Biotherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Wedbush
Cantor Fitzgerald
Wedbush
1calculated from analyst ratings
Analyst Ratings for Artiva Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 1038.61% | Needham | Gil Blum47% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2025 | Buy Now | 890.1% | HC Wainwright & Co. | Edward White48% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2025 | Buy Now | 791.09% | Wedbush | Martin Fan 7% | $18 → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 03/25/2025 | Buy Now | 890.1% | Cantor Fitzgerald | Josh Schimmer50% | $23 → $20 | Maintains | Overweight | Get Alert |
| 03/25/2025 | Buy Now | 1038.61% | Needham | Gil Blum47% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 12/30/2024 | Buy Now | 890.1% | HC Wainwright & Co. | Edward White48% | → $20 | Initiates | → Buy | Get Alert |
| 11/13/2024 | Buy Now | 1038.61% | Needham | Gil Blum47% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2024 | Buy Now | 1038.61% | Needham | Gil Blum47% | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 1038.61% | Needham | Gil Blum47% | → $23 | Initiates | → Buy | Get Alert |
| 08/13/2024 | Buy Now | 791.09% | Wedbush | David Nierengarten59% | → $18 | Initiates | → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 1038.61% | Cantor Fitzgerald | Josh Schimmer50% | → $23 | Initiates | → Overweight | Get Alert |
| 08/13/2024 | Buy Now | — | TD Cowen | Tyler Van Buren45% | — | Initiates | → Buy | Get Alert |
| 08/13/2024 | Buy Now | 939.6% | Jefferies | Kelly Shi39% | → $21 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Artiva Biotherapeutics (ARTV) stock?
The latest price target for Artiva Biotherapeutics (NASDAQ:ARTV) was reported by Needham on April 8, 2025. The analyst firm set a price target for $23.00 expecting ARTV to rise to within 12 months (a possible 1038.61% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Artiva Biotherapeutics (ARTV)?
The latest analyst rating for Artiva Biotherapeutics (NASDAQ:ARTV) was provided by Needham, and Artiva Biotherapeutics reiterated their buy rating.
When was the last upgrade for Artiva Biotherapeutics (ARTV)?
There is no last upgrade for Artiva Biotherapeutics
When was the last downgrade for Artiva Biotherapeutics (ARTV)?
There is no last downgrade for Artiva Biotherapeutics.
When is the next analyst rating going to be posted or updated for Artiva Biotherapeutics (ARTV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Artiva Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Artiva Biotherapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Artiva Biotherapeutics (ARTV) correct?
While ratings are subjective and will change, the latest Artiva Biotherapeutics (ARTV) rating was a reiterated with a price target of $23.00 to $23.00. The current price Artiva Biotherapeutics (ARTV) is trading at is $2.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.